Financial Results for the quarter and year ended as on March 31, 2025
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novartis India reported FY25 revenue from operations of INR 3,562.7 million, up about 6.3% from INR 3,350.7 million in FY24. Full-year profit after tax grew roughly 18% to INR 1,009 million (vs INR 851.9 million), translating to EPS of INR 40.87 (vs INR 34.50). Q4 FY25 was particularly strong, with PAT nearly doubling year-on-year to INR 293 million on revenue of INR 838.8 million. The Board has recommended a final dividend of INR 25 per share, unchanged from the previous year. The statutory auditor (B S R & Co. LLP) issued an unmodified opinion on the results.
Steady topline growth and a healthy jump in profits make this a solid set of numbers for shareholders, with a stable dividend maintaining shareholder returns. The company's balance sheet remains debt-free with strong cash reserves of over INR 6.4 billion, providing comfort on financial stability.